Hypertrophic cardiomyopathy

Article written and reviewed by Dr Luca Moretti

Hypertrophic cardiomyopathy is a myocardial disease in which increased ventricular wall thickness is not explained solely by hypertension, aortic stenosis or other loading conditions sufficient to produce it. The term primarily identifies a phenotype, not a single etiology: the same morphologic category includes the sarcomeric form, many genetic syndromes and some infiltrative or storage diseases. Modern diagnosis must therefore describe morphology, hemodynamics and tissue, then identify the cause. Restricting the description to the word hypertrophy confuses a measurement with a disease and may lead to inappropriate therapies.

In adults, a maximum wall thickness of at least 15 mm in a left ventricular segment supports the diagnosis in the appropriate clinical context. Values of 13 or 14 mm may acquire diagnostic significance in the presence of a causal variant, an affected relative or convincing electrocardiographic and imaging findings. In children, measurements must be normalized for body surface area, age and growth using z-scores because an absolute adult threshold would produce errors. Every measurement requires attention to imaging plane, trabeculations, papillary muscles and image quality.

The distribution of hypertrophy is extremely variable. The basal septum is involved most often, but apical, concentric, midventricular, focal and diffuse forms and right ventricular involvement occur. Geometry influences the mitral apparatus, cavity, pressures and probability of a dynamic gradient. A complete description reports site, maximum thickness, volumes, function, presence of obstruction, mitral regurgitation, scar and aneurysm, avoiding reduction of the entire phenotype to the highest number measured.

The prevalence of the classic phenotype recognized by imaging is close to 0.2% in the adult population, but the number of carriers of potentially relevant sarcomeric variants is higher. Age-dependent penetrance, variable expressivity and subclinical forms explain part of the difference between genetics and clinical diagnosis. Pediatric incidence is much lower and non-sarcomeric causes account for a relatively larger proportion at younger ages. Ancestry, access to imaging and selection criteria modify estimates, so HCM should not be described as a uniform disease in every population.

The contemporary course is less unfavorable than early case series from referral centers suggested. Many people remain asymptomatic or mildly symptomatic for decades, whereas others develop heart failure, atrial fibrillation, ventricular arrhythmias or a systolic phase. Individual risk is not synonymous with the diagnosis and changes over time. Specialist care aims to recognize the trajectory before a complication becomes irreversible without turning every carrier into a fragile patient.

Clinical expression arises from interaction between the biologic substrate and modifiers. The same variant may produce severe infantile onset, modest adult hypertrophy or no recognizable phenotype; blood pressure, obesity, sex, activity, comorbidities and polygenic background contribute to variability. The definition of a sarcomeric form therefore does not authorize deterministic predictions. A genetic diagnosis improves causal attribution and family screening, but prognosis must continue to rest on the observed phenotype and its evolution.

Care requires simultaneous interpretation of the heart and the family. Symptoms, electrocardiogram, echocardiography, magnetic resonance, rhythm, functional testing and pedigree answer different questions and none of these levels is sufficient in isolation. The patient should be reassessed when syncope, persistent palpitations, worsening exercise tolerance, pregnancy or new genetic information arises. The correct model is a longitudinal diagnosis capable of updating phenotype and risk without losing etiologic continuity.

Epidemiology, phenotypes and natural history

Population echocardiographic studies made the estimate of approximately one person in five hundred familiar, but this figure mainly describes recognizable hypertrophy in unselected adults. Systematic screening, magnetic resonance and genetics may identify subtler forms, whereas administrative registries underestimate those who never receive a diagnosis. Clinical prevalence therefore depends on ascertainment intensity. It should not be added uncritically to the frequency of rare variants because not every variant is causal and not every carrier develops hypertrophy.

Age at presentation spans the entire lifespan. Neonatal or infantile onset requires consideration of RASopathies, metabolic, mitochondrial and storage diseases in addition to sarcomeric genes, whereas in older people distinction from amyloidosis and assessment of an age-related sigmoid septum become essential. An identical label may therefore conceal causes with radically different prognoses. Etiologic diagnosis is particularly urgent when neuropathy, weakness, preexcitation, dysmorphic features, renal failure or other extracardiac signs are present.

The asymmetric septal form includes basal, reverse and diffuse configurations and does not automatically imply obstruction. In the basal configuration, elongation of the mitral leaflets, anterior position of the papillary muscles and narrowing of the outflow tract may favor systolic anterior motion. Concentric forms require particularly rigorous comparison with hypertension, Fabry disease and amyloidosis. The morphologic pattern guides diagnosis but alone has no etiologic specificity.

Apical HCM predominantly involves the apex and may be pure or extend to the midsegments. The midventricular form produces an intracavitary narrowing distinct from the outflow tract and may isolate a high-pressure apical chamber. Both may be associated with obliteration, ischemia and aneurysm, but they are not synonymous. In practice, cardiac magnetic resonance is often decisive because echocardiography may foreshorten the cavity or fail to visualize the apex.

Obstruction is defined by a peak instantaneous gradient of at least 30 mmHg at rest or during physiologic provocation. A substantial proportion of patients have no gradient under baseline conditions but develop one with Valsalva, standing or exercise. Classification as obstructive or non-obstructive therefore depends on the quality of gradient assessment, not on a single resting echocardiogram. A value of 50 mmHg is used as a decision threshold in symptomatic patients considered for advanced therapy, not as a new biologic definition.

Natural history includes partially independent trajectories. A person may remain stable with marked hypertrophy, develop atrial fibrillation while preserving ventricular function, experience arrhythmic events without heart failure or progress to systolic dysfunction. Loss of thickness over time does not always equal an end-stage phase because moderate remodeling may occur without severe deterioration. The combination of function, scar, volumes, symptoms and arrhythmic burden defines the meaning of the transformation.

An ejection fraction below 50% identifies the systolic phase of HCM and has important prognostic significance even when the cavity is not dilated. An apparently normal fraction may already accompany reduced strain, low output and substantial diastolic dysfunction because a small cavity ejects a large percentage of a reduced volume. Assessment should not wait for a very low fraction to recognize progression. Increased end-systolic volume and replacement fibrosis may precede obvious decline.

Contemporary cohorts show that heart failure and atrial fibrillation contribute substantially to cumulative burden, especially in patients with a sarcomeric variant and early diagnosis. Mortality therefore does not summarize the entire disease: hospitalizations, limitation, stroke, procedures and family impact can accumulate over decades. Effective follow-up also measures quality of life and functional capacity. The favorable prognosis of many patients must coexist with proportionate surveillance of vulnerable subgroups.

Sex influences recognition and course without creating two separate diseases. Women are often diagnosed later, with more advanced symptoms and functional class, also because the same absolute thickness represents a greater relative burden in a smaller body. Men more often show a phenotype recognized at a young age. Indexing measurements and attention to referral bias reduce differences that cannot be attributed solely to biology.

Childhood onset has a different natural history from adult onset. In infants, heart failure and syndromic causes are relatively more frequent; in adolescence, growth, activity and maturation may accelerate expression. Adult thresholds and models should not be transferred literally, and follow-up should be adapted to the rate of change. Pediatric HCM requires metabolic and genetic expertise in addition to structural cardiology.

An older patient may present with late diagnosis of sarcomeric disease, a phenotype influenced by hypertension or ATTR amyloidosis. Coexisting aortic stenosis, fibrillation and frailty modifies symptoms and invasive options. New hypertrophy should not automatically be attributed to age, but neither is every isolated basal septum inherited HCM. The geriatric context requires causal attribution capable of distinguishing coincidence, interaction and true mimicry.

Genetics, histopathology and molecular mechanisms

Sarcomeric HCM is generally inherited in an autosomal dominant pattern. MYBPC3 and MYH7 account for most molecularly resolved cases, whereas TNNT2, TNNI3, TPM1, ACTC1, MYL2, MYL3 and other genes with robust evidence represent smaller proportions. Truncating MYBPC3 variants often cause haploinsufficiency, whereas many MYH7 missense variants alter the protein that is produced. Variant mechanism, affected domain and quality of evidence are essential to avoid assigning causality to a sequencing finding alone.

The yield of genetic testing is higher in familial disease, young-onset disease and typically sarcomeric phenotypes, but a negative result does not exclude the clinical diagnosis. Overly broad panels increase variants of uncertain significance and may generate false explanations. Classification according to ACMG/AMP criteria must be adapted to the gene-disease relationship and updated when population, functional or segregation data emerge. A VUS cannot be used to predict which relatives will develop the disease.

Penetrance is incomplete and increases with age, while expressivity varies even within the same family. A carrier without hypertrophy may have an abnormal ECG, strain abnormalities, subtle mitral changes or no finding and remains potentially susceptible to developing the phenotype. The term genotype-positive/phenotype-negative describes a current state, not a future guarantee. Family segregation must consider age, examination quality and the possibility that different variants or factors coexist.

Some conditions mimic sarcomeric HCM but require a specific etiologic name. GLA variants cause Fabry disease, LAMP2 causes Danon disease, PRKAG2 causes a syndrome with glycogen storage and preexcitation, whereas amyloidosis and Pompe disease follow different mechanisms. RASopathies and mitochondrial diseases are particularly relevant in pediatrics. Speaking generically of a phenocopy is less informative than identifying the disease because treatment, extracardiac risk and inheritance pattern change.

Macroscopically, the ventricle may show asymmetric hypertrophy, a reduced cavity and abnormalities of papillary muscles or mitral leaflets. Histologically, cardiomyocytes are enlarged and arranged in a disorganized fashion, with irregular cellular connections, interstitial fibrosis and replacement scars. Disarray is not uniformly distributed and small areas may also occur in other settings, so a limited biopsy alone neither confirms nor excludes HCM. Intramural arterioles often show wall thickening and a narrowed lumen.

Sarcomeric variants alter the relationship between energy consumed and force generated, availability of myosin heads, calcium sensitivity and kinetics of the contractile cycle. Hypercontractility observed in many models is not universal for every variant but converges with energetic stress and growth signaling. Cardiomyocytes respond by activating hypertrophic pathways and altering proteostasis, mitochondria and communication with fibroblasts and the microcirculation. The disease is therefore a pathogenetic network, not simply the mechanical effect of a thicker wall.

Fibrosis results both from interstitial expansion and replacement of injured myocytes. CMR with LGE mainly detects focal scar, whereas native T1 and extracellular volume provide information on the diffuse component. Typical distribution includes areas of maximum hypertrophy and right ventricular-septal junctions, but atypical patterns should reopen the differential diagnosis. The fibrotic substrate contributes to stiffness, slowed conduction and arrhythmias without any single value automatically determining ICD implantation.

Modifiers explain part of the discordance between genotype and phenotype. Hypertension and obesity may accentuate mass, symptoms and atrial fibrillation; activity and biologic sex influence age at recognition and adaptation; common variants modulate polygenic risk. This does not turn sarcomeric HCM into a simple multifactorial disease but shows that a monogenic variant operates within a complex organism. Prevention of modifiable factors therefore remains clinically important even when the primary cause cannot be removed.

Multiple variants may coexist in the same individual. Double heterozygosity or a combination of pathogenic variants may be associated with earlier onset or greater severity, but the relationship is not invariable and requires confirmation of the pathogenicity of each finding. Assigning an additive effect to two VUS amplifies uncertainty rather than resolving it. Allelic complexity should be analyzed by an experienced laboratory and interpreted in relation to the family phenotype.

Germline or somatic mosaicism may explain an apparently de novo variant and modify reproductive risk. A variant absent from a parent's blood does not absolutely exclude its presence in a proportion of germ cells, whereas low levels in the proband require technical confirmation. These situations are rare but important in counseling. Recurrence risk should be communicated as an estimate, avoiding both inappropriate zero risk and unsupported percentages.

Research into molecular modifiers includes transcriptomics, proteomics and metabolism, but these tools are not yet part of routine practice. An experimental biomarker should not be presented as a clinical predictor until it demonstrates analytic validity, prognostic validity and decision-making utility. Precision medicine in HCM today rests mainly on etiology, imaging and observable risk, while omics platforms remain a promising research area.

Pathophysiology and clinical manifestations

Diastolic dysfunction arises from delayed relaxation, increased stiffness and reduced ability of the cavity to accept blood without a marked pressure rise. Atrial contraction contributes substantially to filling, especially during exercise, and its loss may precipitate dyspnea and congestion. Conventional Doppler parameters do not fully describe this phenomenon because they depend on preload, rhythm and regional distribution. Filling pressure may rise during exercise while remaining minimally evident at rest.

Outflow tract obstruction results from interaction among the septum, systolic flow, mitral apparatus and loading conditions. Systolic anterior motion of the leaflet, often supported by elongated leaflets and displaced papillary muscles, brings the valve toward the septum and creates a late-peaking gradient. Reduced preload or afterload and increased contractility or heart rate accentuate the phenomenon. Mitral regurgitation is frequently posteriorly directed when SAM-dependent, whereas a different jet suggests an additional valvular lesion.

Ischemia may occur without epicardial stenosis. Increased mass, capillary rarefaction, arteriolar disease, intramyocardial compression, high diastolic pressures and shorter perfusion time reduce coronary reserve. Tachycardia worsens the imbalance and may explain chest pain or elevated troponin. Repeated microvascular ischemia promotes cell death and scar, but concomitant coronary disease should be investigated according to age and clinical probability.

Dyspnea is often multifactorial: stiffness, obstruction, mitral regurgitation, ischemia, chronotropic incompetence, arrhythmias and comorbidities may coexist. Patients tend to adapt their activities and may describe themselves as asymptomatic despite having markedly reduced daily exertion. Questions about stairs, inclines and walking speed are more informative than a generic question about dyspnea. Cardiopulmonary exercise testing distinguishes preserved capacity from hidden limitation and quantifies change over time.

Chest pain may be anginal or atypical and is not specific to the mechanism. Palpitations may reflect ectopy, nonsustained ventricular tachycardia or atrial fibrillation, but also heightened awareness of the heartbeat. Syncope requires reconstruction of posture, exertion, prodromes, medications and recovery because vasovagal causes are common even in HCM. Recent unexplained syncope that is plausibly arrhythmic carries weight in sudden death prevention, unlike a remote clearly situational episode.

Atrial fibrillation results from atrial dilation, pressure and fibrosis and is associated with age and disease burden. Rapid rate and loss of atrial systole may cause pulmonary edema or a marked reduction in output. Embolic risk is higher than predicted by general tools in some patients, so clinical fibrillation is an indication for anticoagulation regardless of CHA2DS2-VASc unless contraindicated. Sinus rhythm has hemodynamic value that justifies early strategies when realistic.

Ventricular arrhythmias arise from the interaction among disarray, scar, ischemia, stretch and adrenergic triggers. Nonsustained tachycardia carries greater weight when frequent, long and fast, especially in younger patients, but does not mean a lethal event is inevitable. An apical aneurysm provides a scar border capable of sustaining monomorphic reentry. Sudden cardiac death may precede heart failure, which is why arrhythmic assessment must be independent of functional class.

Heart failure may present with preserved ejection fraction, obstruction, fibrillation, pulmonary hypertension or systolic dysfunction. In advanced disease the ventricle may dilate, but some people retain small cavities and develop low output because of extreme stiffness. Edema and ascites suggest right-sided involvement or high pulmonary pressures and require reassessment for associated causes. Hemodynamic progression cannot be recognized from a single parameter and requires integration of symptoms, imaging, natriuretic peptides and exercise.

The right ventricle may show hypertrophy, reduced longitudinal function or consequences of pulmonary hypertension. Severe primary involvement is less common and should prompt reconsideration of alternative diagnoses or systemic disease. Right ventricular function becomes particularly important in advanced stages and before replacement therapies. The biventricular profile prevents edema and low output from being interpreted as simple consequences of left ventricular ejection fraction.

Autonomic regulation contributes to symptoms and exercise response. Inappropriate peripheral vasodilation, an attenuated blood pressure response and sensitivity to postural changes may produce presyncope even without arrhythmia. These phenomena do not exclude concomitant electrical risk and require reconstruction of the episode. The vascular response is interpreted together with gradient, heart rate and pressure, avoiding use of a single blood pressure fall as a universal marker.

Mitral regurgitation may be functional because of SAM but also degenerative, calcific or due to intrinsic leaflet abnormalities. Regurgitant volume increases atrial pressure and reduces forward output, contributing to dyspnea and fibrillation. Jet direction and valve structure guide the mechanism. The mitral valve should be evaluated as an independent component when regurgitation does not vary with the gradient or has atypical morphology.

Multimodality diagnosis and differential diagnosis

The electrocardiogram is abnormal in most patients, but no pattern is pathognomonic. High voltages, narrow deep Q waves, ST-T abnormalities, atrial enlargement and conduction blocks may precede visible hypertrophy; giant negative T waves suggest an apical distribution. Low voltages relative to wall thickness suggest amyloidosis, whereas preexcitation points toward PRKAG2, Danon or other diseases. The electrical profile must be interpreted together with age and extracardiac signs.

Echocardiography measures wall thickness, volumes, function, atrium, mitral apparatus and gradient. Views must avoid obliquity and inclusion of nonmyocardial structures; contrast improves endocardial definition when the apex is uncertain. Continuous-wave Doppler searches for the late-peaking dagger-shaped signal and distinguishes it from mitral regurgitation. Physiologic provocation with Valsalva, standing and exercise is necessary when the baseline gradient does not explain symptoms or when the form must be classified correctly.

Magnetic resonance provides coverage of the entire ventricle and reduces errors in focal, apical or poorly visualized anterolateral disease. Cine imaging, LGE, T1, extracellular volume and, when necessary, T2 describe geometry and tissue. Scar distribution aids diagnosis and prognosis, whereas very low T1 suggests Fabry disease and diffuse extracellular expansion with a characteristic pattern points toward amyloidosis. Tissue imaging should nevertheless not replace specific testing when a treatable disease is suspected.

Ambulatory monitoring searches for atrial fibrillation, nonsustained ventricular tachycardia, bradycardia and conduction disturbances. A brief recording may not capture rare symptoms, making prolonged monitoring or an implantable recorder appropriate in selected cases. The significance of an episode depends on duration, frequency, rate and clinical correlation. Rhythm burden is reassessed periodically because it may change before imaging shows obvious progression.

Exercise testing measures capacity, blood pressure, symptoms and arrhythmias and may be combined with echocardiography to seek obstruction. Dobutamine generates nonphysiologic stimulation and is not the standard method for classifying everyday obstruction. Cardiopulmonary exercise testing adds peak oxygen consumption, ventilatory slope and oxygen pulse, useful when limitation is complex or advanced therapy is being assessed. The exercise response reveals pressures and gradients not represented at rest.

The differential diagnosis with athlete's heart considers distribution, cavity size, diastolic function, ECG, detraining and context without relying on a single threshold. Hypertension may produce concentric or septal hypertrophy and may also coexist with genetic HCM; proportionality between load and phenotype is decisive. Aortic stenosis and coarctation require complete hemodynamic assessment. Causal attribution avoids both overdiagnosis in an adapted athlete and false exclusion in a patient with hypertension.

Amyloidosis, Fabry disease, glycogen storage diseases, RASopathies and mitochondrial disorders are investigated using red flags and targeted tests. Serum and urine immunofixation with free light chains precedes possible scintigraphy when ATTR is assessed; enzyme activity and genetics support Fabry diagnosis; CK, lactate, development and neurologic assessment may guide other forms. Endomyocardial biopsy is reserved for cases in which a diagnosis unattainable otherwise changes treatment. Treatable causes must not be missed behind a generic morphologic diagnosis.

Cardiac catheterization is useful when noninvasive data are discordant, a procedure is being planned or pressures and gradient sites need to be distinguished. Coronary angiography assesses coronary anatomy in patients with appropriate probability or before septal therapy. Muscle or other-organ biopsy may be preferable when the disease is systemic. The pathway should be guided by a clinical question: accumulating tests without a hypothesis increases incidental findings and does not necessarily produce a more accurate diagnosis.

Biomarkers do not confirm HCM in isolation. Natriuretic peptides rise with pressure, atrial size, renal function and fibrillation; troponin may reflect microvascular ischemia or stress and must also be interpreted in relation to acute coronary syndrome. CK, transaminases, lactate and metabolic profile are selected according to red flags. Laboratory diagnosis is useful when it translates suspicion into an etiologic choice, not as an undifferentiated universal panel.

Transesophageal echocardiography is not required for routine diagnosis but clarifies the mitral apparatus and subvalvular structures before or during surgery. Three-dimensional imaging shows the relationship among coaptation, papillary muscles and septum and may distinguish SAM from prolapse. Quality depends on acquisition and expertise. Valvular planning uses this modality when the information changes the procedure, avoiding an invasive examination without decision-making consequences.

Serial measurements must be compared with technical variability. A change of two millimeters may result from plane, loading or observer differences, whereas a coherent change in multiple segments, volumes and LGE supports true remodeling. Preserving images and method is essential. Longitudinal follow-up does not consist of placing numbers from different reports side by side but of directly reviewing comparable acquisitions.

Prognostic stratification and prevention of sudden death

Risk stratification distinguishes secondary from primary prevention. A resuscitated cardiac arrest or sustained ventricular tachycardia not attributable to a completely reversible cause constitutes a strong indication for a defibrillator. In primary prevention, the decision is probabilistic and must balance event risk against device complications over an entire lifetime. The implantable cardioverter-defibrillator terminates malignant arrhythmias but does not prevent atrial fibrillation, heart failure or substrate progression.

In adults, a family history of HCM-related sudden death, suspicious syncope, maximum wall thickness of at least 30 mm, apical aneurysm and ejection fraction below 50% are important markers. Nonsustained ventricular tachycardia and extensive LGE further modify the decision, especially when the estimate is uncertain. Each element requires rigorous definition: family history should consider age, degree of relationship and plausibility of the event, not every unexplained death.

The HCM Risk-SCD model estimates five-year risk using age, maximum wall thickness, atrial diameter, gradient, family history, syncope and nonsustained tachycardia. It is useful in the adult population for which it was developed but does not include all modifiers and should not be applied mechanically to children, elite athletes, metabolic diseases or situations not represented. The numerical estimate is a decision aid, not a threshold capable of replacing clinical discussion.

The American approach gives particular weight to major risk factors and shared decision-making; the European approach integrates the calculation with additional modifiers. The two strategies are not mutually exclusive and may illuminate different aspects of the same case. When conclusions diverge, data quality, time horizon, age and patient preferences should be examined. Low risk today still requires periodic reassessment because scar, function and arrhythmias may evolve.

In pediatrics, dedicated tools such as HCM Risk-Kids and PRIMaCY are used because adult predictors do not maintain the same relationship with events. Z-scores for septum and posterior wall, age, atrial size, syncope and tachycardia have specific meanings; genotype and syndromic cause add complexity. The low positive predictive value reminds us that many ICDs implanted for primary prevention will never deliver necessary therapy. Pediatric risk should be discussed at experienced centers and updated during growth and puberty.

Extensive LGE, often quantified around or above 15% of mass, is associated with greater arrhythmic risk, but the threshold depends on technique and analysis. A smaller scar may matter when associated with an aneurysm or other markers, whereas a high value does not make an ICD inevitable without considering age and consequences. T1 and extracellular volume have emerging prognostic value but do not replace established criteria. Fibrosis on CMR is a biologic continuum that should be incorporated into the decision, not converted into a switch.

System choice considers the need for pacing, venous anatomy, age and infection risk. A subcutaneous ICD avoids transvenous leads but does not provide antitachycardia pacing or bradycardia support; a transvenous system offers these functions at the cost of intravascular complications. In young people, revisions and replacements accumulate over decades. Device programming should reduce inappropriate shocks and recognize the rapid atrial arrhythmias common in HCM.

Prognosis is not synonymous with sudden death risk. Atrial dilation, symptoms, cardiopulmonary capacity, pulmonary pressure, ventricular function, mitral regurgitation, kidney disease and hospitalizations describe heart failure and thromboembolic risk. A patient with low arrhythmic risk may have severe hemodynamic limitation, whereas an asymptomatic young person may merit an ICD. Separating prognostic trajectories allows specific interventions to be chosen and absolute values to be communicated without generic alarmism.

Recent exertional syncope without prodromes and without explanation deserves different weight from remote orthostatic loss of consciousness. Monitoring, exercise testing and neurologic or vasovagal assessment are selected according to the history. Labeling every syncope as arrhythmic increases implantations, but declaring it benign without investigation creates the opposite risk. Syncope phenotyping is one of the components most sensitive to clinical judgment.

Family history may be incomplete because of deaths without autopsy, small families, adoption or poor communication. Certificates, autopsies and relatives' reports improve precision when available. Sudden death at an advanced age with coronary disease does not carry the same meaning as an unexplained event in a young person. Pedigree validation reduces both the weight assigned to coincidences and the loss of truly hereditary signals.

Increasing LGE may accompany progression, but repeat magnetic resonance should account for differences in scanner and method. Manual or automated quantification varies with the threshold used, and a percentage is not perfectly transferable among laboratories. Clinical significance increases when the change agrees with function and arrhythmias. CMR standardization is necessary before small differences are interpreted as acceleration of disease.

Pharmacologic and interventional treatment

Treatment begins with the mechanism responsible for symptoms. In the obstructive form, nonvasodilating beta-blockers reduce heart rate and contractility and are a common first choice; verapamil or diltiazem are alternatives in appropriate patients, with caution in hypotension, very high pressures or congestion. Disopyramide may add a negative inotropic effect but requires monitoring of QT and anticholinergic effects. Titration should measure capacity and tolerability rather than pursue an arbitrary heart rate.

Myosin inhibitors reduce the number of heads available for contraction and may lower gradients and symptoms. Mavacamten demonstrated benefit in EXPLORER-HCM and reduced the need for septal therapy in VALOR-HCM; aficamten improved capacity and clinical status in SEQUOIA-HCM and has been authorized in the European Union since 2026 for adults with symptomatic obstructive HCM. Both require specialist management of systolic function and interactions according to their respective regulatory information. They are not automatically interchangeable in dose, pharmacokinetics or monitoring.

Septal reduction is intended for patients with limiting symptoms attributable to a gradient of at least 50 mmHg despite optimized or intolerable therapy. Myectomy removes the responsible septum and permits correction of associated papillary or mitral abnormalities. Alcohol ablation produces controlled necrosis in the territory of a septal branch and depends on favorable coronary anatomy. Procedural selection considers age, comorbidities, wall thickness, valve, coronary anatomy, risk of block and center expertise.

In the non-obstructive form, beta-blockers or calcium-channel blockers may relieve palpitations, ischemia or dyspnea in some patients, but evidence for a specific prognostic benefit is limited. Small doses of diuretics treat congestion while avoiding excessive reduction in filling. ODYSSEY-HCM did not demonstrate significant improvement in the two primary endpoints with mavacamten in symptomatic non-obstructive HCM, so the result does not justify automatic extension of the indication. Symptomatic therapy should remain cautious and verify comorbidities, heart rate and objective response.

When ejection fraction falls below 50%, principles of heart failure therapy for reduced function are applied, adapted to blood pressure, cavity size and tolerance. Drugs with marked negative inotropic effect are reassessed, while investigation for ischemia, arrhythmia and other causes of deterioration accompanies neurohormonal therapy. Resynchronization may be considered in patients meeting appropriate criteria. Heart transplantation should be discussed before fixed pulmonary hypertension, renal injury or deconditioning makes risk excessive.

Clinical atrial fibrillation requires anticoagulation in the absence of contraindications, generally with a direct oral anticoagulant in eligible patients. Cardioversion, antiarrhythmics and ablation are chosen according to duration, atrial size, symptoms and previous attempts, recognizing a higher probability of recurrence. Rate control should avoid excessive bradycardia and loss of chronotropic capacity. Stroke prevention should not wait for a high CHA2DS2-VASc score in HCM.

Ventricular tachycardia ablation may reduce episodes and shocks in patients with a defined circuit, particularly in the presence of an apical aneurysm, but does not eliminate substrate progression. Antiarrhythmics are used as an adjunct and should be selected with attention to function and proarrhythmia. The ICD remains essential protection when risk justifies implantation. An electrical storm requires stabilization, correction of triggers, drugs, device programming and coordinated assessment for ablation.

Management of comorbidities is part of HCM treatment. Hypertension, obesity, obstructive sleep apnea, diabetes and coronary disease increase symptoms and heart failure; their treatment must respect obstructive hemodynamics. Vasodilators and diuretics are not absolutely prohibited but may worsen a gradient in preload-dependent individuals. Hemodynamic personalization avoids both unjustified discontinuation of necessary therapies and automatic application of schemes designed for other phenotypes.

Acute heart failure management depends on the mechanism. An obstructive hypovolemic patient requires cautious restoration of preload and control of tachycardia, whereas a congested non-obstructive patient may require more decisive diuresis. Bedside echocardiography distinguishes gradient, regurgitation and function. Emergency therapy should prevent inotropes or vasodilators from worsening an unrecognized dynamic obstruction.

Arterial hypertension is treated without ignoring the gradient. A beta-blocker may satisfy both indications but does not always control pressure adequately; other agents are added with titration and symptom verification. Leaving important hypertension untreated does not protect against obstruction and promotes remodeling. Blood pressure control balances reduction of chronic load and hemodynamic stability rather than applying absolute prohibitions.

Concomitant coronary artery disease requires preventive therapy and revascularization according to anatomy and ischemia. Pain should not always be attributed to the microcirculation, especially in older patients or those with risk factors. Before myectomy, knowledge of coronary anatomy may modify the surgical plan. Dual pathology requires distinguishing what depends on HCM from what depends on a treatable stenosis.

Family, physical activity, pregnancy and follow-up

The proband undergoes genetic counseling before and after testing. A pathogenic or likely pathogenic variant allows cascade testing to be offered to relatives; those who do not carry the familial variant can generally stop screening related to that cause, whereas carriers continue follow-up. If testing is negative or identifies a VUS, first-degree relatives receive clinical surveillance based on the pedigree. Family screening cannot be replaced by an ambiguous molecular report.

Intervals and modalities depend on age, symptoms, family history and genotype. ECG and echocardiography form the basis, with magnetic resonance when imaging is incomplete or uncertainties exist; in childhood, growth and puberty justify more frequent checks. A normal examination does not exclude future expression. Pediatric-to-adult transition must preserve genetic history, serial measurements and responsibility for follow-up, preventing a young carrier from disappearing from surveillance.

Regular light- or moderate-intensity physical activity is encouraged in most patients. LIVE-HCM did not observe an increase in events in the group reporting vigorous exercise compared with those performing nonvigorous activity, but it was an observational study in people assessed and followed at expert centers. Competitive participation requires shared decision-making integrating symptoms, history, arrhythmias, obstruction, function, type of sport and possibility of reassessment. A universal ban promotes sedentary behavior and metabolic harm.

Pregnancy is tolerated by many women with stable HCM, but risk increases with important symptoms, severe obstruction, arrhythmias or ventricular dysfunction. Preconception assessment reviews medications, maternal risk, inheritance and delivery planning; myosin inhibitors require particular attention to reproductive risk according to the prescribing information. During gestation, changes in volume and heart rate may modify gradients and symptoms. The cardio-obstetric team coordinates follow-up, anesthesia, delivery and the postpartum period.

Reproductive counseling explains an often 50% probability of transmitting an autosomal dominant variant but also the inability to predict severity and age at onset precisely. Prenatal diagnosis and preimplantation genetic testing are options, not obligations, and require a defined causal variant. The decision belongs to the person or couple after nondirective information. Prognostic uncertainty should be communicated as clearly as the inheritance pattern.

Routine follow-up assesses new symptoms, blood pressure, rhythm, ECG, echocardiography and sudden death risk. Ambulatory monitoring is repeated and prolonged when palpitations or risk factors for fibrillation exist; magnetic resonance is repeated when it can change diagnosis or decisions, not automatically every year. Exercise and cardiopulmonary testing document capacity and provocable obstruction. Earlier reassessment is necessary after syncope, rapid worsening, pregnancy, family events or major therapeutic changes.

HCM affects work, sport, insurance, driving and perception of the future. Uncontextualized information about sudden death may generate avoidance, whereas minimizing symptoms and family history undermines adherence. Communication should distinguish absolute risk, the period considered and available interventions, involving the patient in decisions about ICDs, drugs and procedures. Quality of life is a clinical endpoint and not an accessory to imaging measurements.

Expert centers are particularly important when the diagnosis is uncertain, myosin inhibitor therapy, septal reduction, complex ablation, an ICD in a young person or transplantation is being considered. This does not exclude collaboration with local cardiology, which ensures continuity, control of comorbidities and timely access. An effective network shares reports, medications and warning thresholds. Multidisciplinary care includes imaging, electrophysiology, genetics, cardiac surgery, heart failure, pediatrics and obstetrics as needed.

Driving recommendations depend on syncope, arrhythmias, ICD and national regulations, not on the diagnosis alone. An appropriate shock or unexplained loss of consciousness requires suspension and reassessment according to current rules. Clear information avoids both risk and unnecessary occupational sacrifices. Fitness to drive should be documented and updated when the clinical profile changes.

Noncardiac surgery requires assessment of the gradient, volume, rhythm and therapy. Fasting, anesthesia, vasodilation and bleeding may destabilize an obstructive form; tachycardia and pain increase demand. Not every procedure requires an HCM center, but the anesthesia team should understand the mechanism. Perioperative planning maintains preload and blood pressure and anticipates arrhythmia management.

Patient information includes a plan for fever, dehydration, new medications and warning symptoms. An indiscriminate list of prohibitions is difficult to follow and does not replace understandable principles. Knowing why a condition increases gradient or heart rate permits safer decisions. Informed self-management supports adherence and timely contact without turning every physiologic variation into an emergency.

Complications and long-term prognosis

Chronic obstruction increases ventricular work and pressures, contributes to mitral regurgitation and may progressively limit exercise. The gradient varies with daily conditions and does not maintain a linear relationship with perceived symptoms. One patient may adapt by reducing activity while another tolerates high values. The obstructive complication should be treated when it produces attributable limitation, not merely because a high number appears in a report.

Atrial fibrillation exposes patients to hemodynamic deterioration and thromboembolism. Atrial dilation, age and fibrosis increase probability, but clinically relevant episodes may occur before marked dilation. Monitoring and anticoagulation have reduced stroke in modern cohorts. Atrial burden also includes recurrences, hospitalizations and failure of rhythm strategies, which may become the principal cause of reduced quality of life.

An apical aneurysm is a thinned akinetic or dyskinetic region that may be difficult to recognize without contrast or magnetic resonance. The scar border promotes ventricular tachycardia and stasis promotes thrombus; size and progression should be documented serially. In the presence of thrombus, anticoagulation is indicated, whereas prophylaxis without thrombus or fibrillation requires individualization because evidence is less definitive. The aneurysm is also a major risk factor in the American ICD assessment.

The systolic phase affects a minority but carries a high risk of heart failure, arrhythmias and transplantation. An ejection fraction below 50% is already abnormal in HCM even if it would be considered only moderately reduced in other settings. Increasing scar and remodeling may be gradual, allowing a window for therapy and referral. Ventricular dysfunction requires that every deterioration not be attributed automatically to HCM: epicardial ischemia, tachyarrhythmia, medications and valvular disease may contribute.

Pulmonary hypertension may result from high left-sided pressures, mitral regurgitation, fibrillation and vascular remodeling. When severe, it worsens symptoms, right ventricular function and transplant candidacy. Echocardiography, functional testing and catheterization in appropriate cases clarify reversible components and output. Right-sided congestion should not be treated only with escalating diuretics without reassessing the dominant left-sided mechanism.

Iatrogenic complications include drug-induced bradycardia and hypotension, systolic dysfunction from excessive myosin inhibition, atrioventricular block after septal reduction, inappropriate shocks, infection and lead failure. Prevention requires expertise, monitoring and proportionate indications. The benefit of an excellent procedure can be negated by improper selection. Therapeutic safety should be measured with the same rigor as the gradient or functional class.

Modern prognosis is favorable for most patients but cannot be expressed by a single rate. Early onset, sarcomeric genotype, obstruction, fibrillation, aneurysm, extensive LGE and dysfunction identify different pathways; effective treatments also modify observed risk. Historical series overestimate events when applied indiscriminately, whereas recent registries do not eliminate individual risk. Prognostic communication should use contemporary data, explain uncertainty and indicate which factors can be monitored or treated.

Success of care does not consist solely of absence of sudden death. It includes stroke prevention, maintenance of capacity, reduction of hospitalizations, preservation of function, reproductive management and early identification of relatives. Every new therapy modifies one part of natural history and requires long-term surveillance. Integrated care that is updated and family-centered transforms HCM from a diagnosis perceived as fatalistic into a chronic disease in which many complications can be prevented or treated.

Chronic mitral regurgitation may persist after gradient control if an organic lesion exists, whereas purely SAM-related regurgitation tends to decrease. Failure to distinguish the two exposes patients to residual congestion or excessive procedures. Valve, atrium and pulmonary pressure are reassessed together. The valvular complication therefore requires mechanistic follow-up rather than grading of the jet alone.

Stroke may result from known fibrillation, subclinical episodes or ventricular thrombus in an aneurysm. After an event, prolonged monitoring and imaging search for the source, while anticoagulation is adapted to mechanism and bleeding risk. Antiplatelet therapy does not replace anticoagulation in HCM atrial fibrillation. Secondary prevention should begin without delay but be reassessed when new information emerges.

Transplantation offers favorable survival and quality of life to selected patients with end-stage disease, but late referral reduces eligibility. Low output, oxygen consumption, hospitalizations, right ventricular function and pulmonary pressure are assessed together. Preserved ejection fraction does not exclude candidacy. The transplant window is recognized from the trajectory rather than by crossing a single threshold.